



PRESS RELEASE

For immediate release

PERCEPTRONIX BRINGS EARLY LUNG CANCER DETECTION TO UK BY SIGNING SERVICE AGREEMENT WITH UNIVERSITY HOSPITAL OF COVENTRY AND WARWICKSHIRE NHS TRUST

VANCOUVER, CANADA (May 28, 2007) - Perceptronix Medical Inc. ("Perceptronix") announced it has signed a service agreement for its LungSign™ test (formerly ClearSign™) with University Hospital of Coventry and Warwickshire (UHCW) NHS Trust in the UK.

Starting June 1st, 2007, the Trust will receive and disperse LungSign™ collection kits to local family practitioners. Samples will be processed at the Perceptronix Laboratory in Vancouver, Canada.

Dr. David Snead, Head of Histopathology, UHCW and Dr. Paul Dhillon, Head of Respiratory Medicine, UHCW were the principal investigators for two LungSign™ clinical trials. Dr. Snead says "This test will substantially improve current practice in sputum cytology and we expect increase in early diagnosis of lung cancer which will enable detection at a stage for which effective therapies already exist."

Dr. Bojana Turic, CEO of Perceptronix commented, "We are delighted by the endorsement from our investigators. Drs Snead and Dhillon recognize that LungSign™ can aid in the early diagnosis and treatment of lung cancer in their patients." Dr. Turic continues, "This agreement represents an important and exciting step for Perceptronix' commercialization efforts."

About LungSign™(formerly ClearSign™)

LungSign™ has been designed to test for early-stage, pre-symptomatic lung cancer in high-risk individuals — men and women over 40 years old, with a history of cigarette smoking, exposure to second-hand smoke, or significant exposure to carcinogens such as radon and asbestos. In addition, for patients who have had CT scans that found small, possibly cancerous nodules, LungSign™ results may help shorten the diagnostic process.

When it comes to lung cancer, early detection is key to extending lives and improving the quality of life for those who are ill. LungSign™'s innovative technology brings new hope to the battle, with a safe, simple, non-invasive test for the early detection of lung cancer. By analyzing the lung cells commonly found in sputum, LungSign™ can detect cancer before it spreads, increasing the likelihood of successful treatment.

About Perceptronix Medical Inc. (www.perceptronix.com)

Perceptronix Medical Inc. (founded in 1999) is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with the BC Cancer Agency, a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs.



Perceptronix' products and services offer an improvement over existing detection and localization technologies and provide physicians with increased options for prolonging and improving the quality of patients' lives.

**University Hospitals Coventry and Warwickshire NHS Trust Coventry, UK
(<http://www.uhcw.nhs.uk>)**

The flagship Clinical Sciences Centre, one of the largest and most modern healthcare education centres in Europe has been built on the site of the new University Hospital and combines teaching facilities including a mock operating theatre and ward, research laboratories and a state of the art library to create a leading edge knowledge centre for the NHS in the midlands.

This news release is not, and under no circumstances, to be construed as, an advertisement, solicitation or offering of securities of Perceptronix Medical Inc. The statements made in this news release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations.

Contact:

Dr. Bojana Turic
President, CEO
Perceptronix Medical Inc.
Phone: (604) 629-8785
info@perceptronix.com

Media Contact:

Amanda Smith, BSc
Smith Biotech
Phone: (778) 846-4116
amanda@smithbiotech.com